apl-2
apl-2: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Apellis Pharmaceuticals, Inc. (APLS)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) | Phase 3 |
Clinical Trials (1)
A Phase 3B, Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety of Pegcetacoplan in a Prefilled Syringe in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Frequently asked questions
Who is developing apl-2?
apl-2 is being developed by Apellis Pharmaceuticals, Inc..
How many clinical trials involve apl-2?
BioSniper tracks 1 clinical trial involving apl-2.
Analyze Apellis Pharmaceuticals, Inc. & apl-2 with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company